// doses studied
Ipamorelin dosage, as it appears in the studies — not as a recommendation.
The doses, routes, and half-life reported in the literature, in third person, with the figures attached to their sources.
Read this first
This page reports the ipamorelin dosage figures that appear in published studies. It is not a dosing guide and contains no instruction for any person to take anything. Ipamorelin is not an approved drug, so there is no labeled human dose to cite — only what researchers gave to animals and, in two small studies, to volunteers. In rats, bone studies used microgram-per-day amounts split through the day; in humans, the only doses were given by IV drip in a lab. The compound clears from human blood with a half-life of roughly 2 hours, and the growth-hormone burst it triggers peaks about 40 minutes after a dose. Community "stack" routines that pair it with CJC-1295 by subcutaneous injection have no controlled human dosing evidence behind them, and this page treats them as exactly that — unverified.
Doses studied in animals
Rodent skeletal work used subcutaneous microgram-range doses divided across the day. The defining bone-growth study gave 18, 90 and 450 microg/day SC, split three times daily for 15 days, and saw a stepwise rise in longitudinal bone growth rate [2]. A bone-mineral study delivered 0.5 mg/kg/day continuously by osmotic minipump for 12 weeks [3]. A steroid-rescue study used 100 microg/kg SC three times daily for 3 months [4], and a related study delivered 0.4-1.6 mg/kg/day IV in four divided doses to probe the growth-hormone response under glucocorticoid load [5].
Other models pushed higher and used different routes. Rat postoperative-ileus work used 0.1-1 mg/kg IV repeated four times daily, and the 2024 ferret cachexia study used 1-3 mg/kg intraperitoneal [8]. Across these, the route, frequency, and dose were chosen for the experimental question — they are not a template for anything outside the lab.
Doses studied in humans
Human dosing exists in just two published settings, both intravenous and lab-administered. The pharmacology study infused single doses of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes in healthy men to map the kinetics [6]. The Phase 2 ileus trial gave 0.03 mg/kg IV twice daily for up to 7 days in 114 bowel-resection patients [7]. There is no published human subcutaneous dosing study, despite subcutaneous injection being the dominant route in off-label use — a gap stated plainly on the Ipamorelin effects page.
Half-life and pharmacokinetics
In healthy human volunteers ipamorelin showed a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg, with dose-proportional (linear) kinetics across the studied range [6]. The pharmacodynamic readout was a single discrete growth-hormone pulse peaking at about 0.67 h — roughly 40 minutes — after dosing [6]. In rats, plasma clearance is reported to be roughly five-fold lower than that of GHRP-6. The short half-life and single-pulse profile are why community protocols emphasize timing rather than continuous exposure, though no human study validates any such schedule.
Routes studied
Five routes appear in the literature, each tied to a purpose. Intravenous dosing carries the human PK and clinical-trial data and much of the rodent efficacy work [6] [7]. Subcutaneous dosing dominates the rodent bone and body-composition studies and is the most common route in community use [2] [3]. Intranasal delivery has been characterized in rodents at roughly 20% bioavailability. Intraperitoneal dosing appears in rodent and ferret efficacy studies [8]. Oral dosing applies only to engineered ipamorelin-derived analogs (about 10% bioavailability in dog); ipamorelin itself is not orally bioavailable.
How to reconstitute cjc-1295 ipamorelin 5mg
Reconstitution questions come up constantly for the CJC-1295/ipamorelin combination, and the honest answer is a handling note, not a protocol. Research peptides like ipamorelin ship as a lyophilized (freeze-dried) powder — free base or acetate salt — and are reconstituted with bacteriostatic water for laboratory handling; as peptides they degrade with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated [6]. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and no specific volume or concentration is endorsed here because there is no approved human formulation to anchor one to.
How much cjc-1295 ipamorelin should i take
There is no evidence-based answer to how much CJC-1295/ipamorelin a person should take, because no controlled human trial has tested the combination for any outcome [16]. Community "stack" protocols pair the two by subcutaneous injection, but those regimens have no peer-reviewed human dosing basis and are anecdotal, not recommended [7]. The only human ipamorelin doses ever published were intravenous and lab-administered [6] [7]. This site reports those study figures in third person and does not convert them into a personal dose.
Is cjc-1295 ipamorelin safe
Whether CJC-1295/ipamorelin is safe cannot be answered from controlled human data, because none exists for the combination. The single ipamorelin Phase 2 trial showed no ipamorelin-specific safety signal over a 7-day IV window [7], but a 28-day study of a related GHS-R1a agonist found dose-dependent heart-muscle damage in rats [9], and long-term cardiovascular safety of chronic ipamorelin dosing in humans is uncharacterized. The cited safety cautions — cancer, glucose, cardiovascular, appetite — are detailed on the Ipamorelin effects page.
Is ipamorelin fda approved
Ipamorelin is not FDA approved for any indication. It was investigated for postoperative ileus (NCT00672074) but the trial missed its primary endpoint [7], and no Phase 3 followed. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening compounding-pharmacy access. It is marketed only as a research chemical, and it is prohibited in sport at all times under WADA category S2.